Prime Medicine (PRME) Research & Development (2021 - 2026)

Prime Medicine has reported Research & Development for 6 years, with the latest figure at $34.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 15.92% year-over-year to $34.1 million; the trailing twelve-month figure through Mar 2026 stood at $154.2 million (down 2.47% YoY), and the FY2025 full-year result was $160.6 million, up 3.44% from the prior year.
• Research & Development for Q1 2026 stood at $34.1 million, down from $34.7 million in the prior quarter.
• The five-year high for Research & Development was $44.0 million in Q3 2025, with the low at $13.7 million in Q1 2022.
• Historically, Research & Development has averaged $34.4 million across 5 years, with a median of $34.7 million in 2025.
• The largest YoY upside for Research & Development was 238.47% in 2022 against a maximum downside of 45.05% in 2022.
• Prime Medicine's Research & Development stood at $29.1 million in 2022, then jumped by 42.66% to $41.5 million in 2023, then dropped by 17.74% to $34.1 million in 2024, then increased by 1.77% to $34.7 million in 2025, then dropped by 1.74% to $34.1 million in 2026.
• The last three Research & Development figures came in at $34.1 million (Q1 2026), $34.7 million (Q4 2025), and $44.0 million (Q3 2025), per Business Quant data.